Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 5,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Agent Clear all

Conditions: HIV Infections
Interventions: Interferon beta-1b, Zidovudine; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Berkeley, California • Los Angeles, California • Oakland, California + 13 more

Conditions: Total Knee Arthroplasty
Interventions: Study Group: Experimental, Control Group; Procedure
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 90 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Platinum-resistant Ovarian Cancer
Interventions: Batiraxcept, Paclitaxel, Placebo; Drug · Other
Lead sponsor: Aravive, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 84
States / cities: Mobile, Alabama • Burbank, California • Los Angeles, California + 74 more

Conditions: Lung Cancer
Interventions: carboplatin, paclitaxel; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2006
U.S. locations: 35
States / cities: La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more

Conditions: Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
Interventions: Lenvatinib, Ifosfamide, Etoposide; Drug
Lead sponsor: Eisai Limited; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Coronavirus Disease 2019 (COVID-19)
Interventions: AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]); Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Modesto, California • Westminster, California + 13 more

Conditions: Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations, AML, Leukemia
Interventions: Revumenib, Midostaurin, Cytarabine, Daunorubicin; Drug
Lead sponsor: Richard Stone, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: New Haven, Connecticut • Boston, Massachusetts

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions: Natural Killer Cell Therapy, Temozolomide; Biological · Drug
Lead sponsor: Kari Kendra; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Melanoma
Interventions: glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab), glembatumumab vedotin and CDX-301; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Fort Myers, Florida + 10 more

Conditions: Malignant Melanoma
Interventions: Drug cocktail, RO5185426; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Severe Combined Immunodeficiency
Interventions: AProArt-CD34, CliniMACS® CD34 Reagent System cell sorter device, Busulfan; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 2 Months and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2038
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Solid Tumors
Interventions: TAS-102; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 10
States / cities: Phoenix, Arizona • Duarte, California • Santa Monica, California + 6 more

Conditions: Biological Availability, Healthy Participants
Interventions: Nirmatrelvir/ ritonavir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stress Disorders, Post-Traumatic, Alcohol Abuse, Substance-Related Disorders
Interventions: Seeking Safety, Sertraline, Pill placebo; Behavioral · Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure
Interventions: Epclusa; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 90 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Los Angeles, California • Durham, North Carolina • Dallas, Texas

Conditions: Small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer
Interventions: Thoracic Radiation Therapy, Ipilimumab, Nivolumab; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions: AZD4512 monotherapy; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Duarte, California • Jacksonville, Florida • Chicago, Illinois + 3 more

Conditions: Infection, Acute Kidney Injury, Sepsis
Interventions: Piperacillin + Tazobactam, meropenem; Drug
Lead sponsor: Bassett Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 852 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Worcester, Massachusetts • Omaha, Nebraska • Cooperstown, New York + 4 more

Conditions: Covid19
Interventions: Antiviral Agents, Monoclonal antibody; Drug
Lead sponsor: Pregistry; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: Zidovudine, Acetaminophen; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Low Anterior Resection Syndrome, Rectal Carcinoma
Interventions: Dietary Fiber, Enema Administration, Loperamide Hydrochloride, Physical Therapy, Questionnaire Administration, X-Ray Imaging; Dietary Supplement · Procedure · Drug + 1 more
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Opioid-use Disorder
Interventions: Buprenorphine Naloxone; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Non Hodgkin Lymphoma, Solid Tumor
Interventions: SB-4826, Rituximab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Pediatric Heart Failure
Interventions: LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 25
States / cities: Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more

Search by objective public record fields.

Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen

Saphenous Nerve Block Versus Femoral Nerve Block for Total Knee Arthroplasty

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19

Revumenib in Combination With 7+3 + Midostaurin in AML

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Autologous Gene Therapy for Artemis-Deficient SCID

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

Combined Treatment for Alcohol-Dependent Individuals With PTSD

Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients

Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

COVID-19 International Drug Pregnancy Registry

Evaluation of the Interaction Between Acetaminophen and Zidovudine

A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients

Buprenorphine Loading in the Emergency Department

SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure